biotech acquisition rumors

Beginning on February 10, 2012, Voce Capital sent a letter to the Obagi Board of Directors criticizing the Board's adoption of a poison pill and demanding immediate action to address the company's corporate governance failures. Here's a look at the 10 top takeover targets. Here's the Stock to Buy Now, Join Nearly 1 Million Premium Members And Get More In-Depth Stock Guidance and Research, Motley Fool Issues Rare All In Buy Alert, Copyright, Trademark and Patent Information. You can incur substantial financial losses in any trade or investment. The results of one of biotech's most polarizing clinical trials, an Alnylam Pharmaceuticals study in a rare disease known as transthyretin amyloidosis cardiomyopathy, are expected imminently. PwC. Later, Bristol-Myers Squibb for $2.4B. Copyright Biotech Investments 2022 | Switzerland | All rights reserved. Brian, what are some acquisitions that you'd like to see take place in the biopharmaceutical world in 2022. Sold Kos Pharmaceuticals to Abbott Laboratories (ABT): Mr. Adams served as the President and Chief Executive Officer of Kos Pharmaceuticals, Inc. Abbott Laboratories bought out Kos Pharmaceuticals for $78 a share, or a 56% premium over the current share price. Its lead product candidate, pimavanserin, designed to treat Parkinson's Disease Psychosis (PDP) has completed a. e have heard similar buzz over the last few months, and as mentioned, the buzz makes sense to us, in no small part because Acadia has had quite an epic stock run over the last year. Antares Pharma. Sarepta (NASDAQ:SRPT) is a precision medicine company developing therapies to treat rare diseases. Sold Tercica to Ipsen: Mr. King served as President and General Manager of Tercica. While oncology and immuno-oncology are the key areas of focus, treatments for rare diseases and gene-editing companies also promise potential, making them lucrative investment areas. Additional disclosure: Disclaimer: This article is intended for informational and entertainment use only, and should not be construed as professional investment advice. Biotech/FDA. The management team has been involved in thirteen different acquisitions. The FDA has accepted the new drug application for adagrasib in NSCLC, with a PDUFA goal date of Dec. 14, 2022. 4. Stay on top of what's happening at JPM. 10 stocks we like better than Bristol Myers SquibbWhen our award-winning analyst team has a stock tip, it can pay to listen. Leading gene-editing biotechs CRISPR Therapeutics and Intellia are likely to be acquired at some point. Furthermore, Antares and Pfizer entered into a collaboration in December 2011 for a yet still undisclosed product. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services. Hunzinger said: Biotech and smaller medical device deals should continue in the first half of the year, with the second half poised for larger deals driven by a need for scale and an expected settling of the regulatory landscape.. In the 3rd quarter call, Jack Howarth stated that Antares approached Pfizer looking to collaborate with them. Best Penny Stocks . Since then, Alnylam has received FDA approval for several drugs and has developed a robust development pipeline. The average deal size also shrank from the historical mean of $4.3 billion to $2.8 billion. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*. Just recently, Bayer bought out Conceptus for $1.1B. They just revealed what they believe are the ten best stocks for investors to buy right now and Bristol Myers Squibb wasn't one of them! Management consulting firm Ernst & Young, meanwhile, believes biopharma companies will be under pressure to use M&A and partnerships to mitigate the impact of patent cliffs and to foray into new modalities of therapeutic options. Cost basis and return based on previous market day close. Moreover, companies investing in mRNA technology are gaining a lot of attention, given the success of the technology in the development of COVID-19 vaccines. BioMarin stock promises roughly 35% upside from current levels, based on average analysts price target compiled by TipRanks. Alnylams commercial RNAi therapeutic products are Onpattro (patisiran), Givlaari (givosiran), Oxlumo (lumasiran), as well as Leqvio (inclisiran), with partner Novartis, which has obtained global rights to develop, manufacture and commercialize inclisiran under a license and collaboration agreement. Pharma giant Pfizer recently announced that it will acquire Arena. *Stock Advisor returns as of January 10, 2022. Are you interested in learning more about small- and mid-cap biotech stocks with exceptional growth potential and some of the hottest takeover targets of the industry? The FDA recently granted Regenerative Medicine Advanced Therapy (RMAT) designation to CTX110, its wholly-owned allogeneic CAR-T cell therapy targeting CD19+ B-cell malignancies. Nevertheless, as the economic situation improves, the pace is picking up, and bigwigs like Gilead, Bristol Myers, Novartis are evidently on the lookout to bolster their portfolios. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. 2023, Nasdaq, Inc. All Rights Reserved. Johnson & Johnson merged with ALZA Corporation for a $10.5B stock for stock transaction. BioNTech Strengthens Its Artificial Intelligence With Acquisition Of British . Its lead product candidate, pimavanserin, designed to treat Parkinson's Disease Psychosis (PDP) has completed a sucessfull phase III trial in November of last year. Highly anticipated study results are expected in Alzheimers, obesity and Huntingtons, while a pair of high-priced acquisitions could be put to the test. The company has three marketed products and boasts of a vibrant pipeline, with a host of investigational therapeutics. Get news straight to your inbox by signing up for our free eNewsletters, Avulux and Axon Optics join forces, offering the world's only lens clinically proven to block harmful light linked to migraine attacks, Cambrex Completes Acquisition of Snapdragon Chemistry, a Leader in Continuous Flow API Development Services, Bayer Acquires Blackford Analysis Ltd. Bolstering the Companys Position in Digital Medical Imaging, Leap Jumps Ahead in Cancer Game with Flame Merger, Elicio Therapeutics Enters Into Merger Agreement with Angion Biomedica, Leap Therapeutics Acquires Flame Biosciences, Calyxt and Cibus Announce the Signing of a Definitive Merger Agreement, Ra Medical Systems Realigns Its Board of Directors, Shockwave Medical Announces Agreement to Acquire Neovasc, Calyxt and Cibus Announce Definitive Merger Agreement to Create Industry-Leading Precision Gene Editing and Trait Licensing Company, Aegis Sciences Corporation Acquires HealthTrackRxs Toxicology Business Unit, Elicio Therapeutics and Angion Enter into Definitive Merger Agreement, How to Prepare if Your Company is Being Acquired, Calibre Scientific Acquires Glass Chemicals, a Comprehensive Provider of Laboratory Consumables, Equipment and Services in Spain. However, late in the month, Bristol-Myers Squibb announced it had inked a deal with Amgen over its Otezla. Calyxt, Inc. (Nasdaq: CLXT), a plant-based synthetic biology company, and Cibus, a leader in precision gene editing in agriculture, today announced that both companies have entered into a definitive merger agreement under which Calyxt and Cibus will merge in an all-stock transaction. Calibre Scientific is pleased to announce the acquisition of Glass Chemicals, a Spanish distributor of scientific consumables, equipment and services for the life sciences, diagnostics, and industrial sectors. Given that the FDA is yet to approve a NASH drug, it is worth taking a risk with this one-trick pony. Sold ATS Medical, Inc. to Medronics Inc. (MDT): Mr. Nohra served on the Board of Directors of ATS Medical, Inc. Medronics bought out ATS Medical for $370M. Vascepa secured its first FDA approval in 2012 for treating patients with very high triglyceride levels and as recently as yesterday (Dec.14) was approved for wider use, i.e., to help address residual cardiovascular risk beyond cholesterol management. Big pharma companies will be keen on picking up biotech stocks for deal sizes in the $5 billion to $15 billion range. This biotechnology company, which operates in hemophilia and ultra-orphan disease drug space, has seven approved treatments, a strong pipeline, and steadily growing revenue. We have been hearing some strong acquisition rumors concerning AcelRx, much like we heard about Obagi last year. Bayer announced the acquisition of the global strategic imaging AI platform and solutions provider Blackford Analysis Ltd. Aesther Healthcare Acquisition Corp (NASDAQ: AEHA) Announces Filing of Definitive Proxy Statement with SEC in Connection with its Proposed Business Combination with Ocean Biomedical, Inc. Capsa Healthcare Acquires Tryten Technologies to Strengthen Its Leadership Position in Mobile Computing. Keith Speights: All right, Brian. Click on an acquiring company to pull up more information, and scroll to the bottom of the page to read how this information was collected and organized. Pharma giant Pfizer recently announced that it will acquire Arena Pharmaceuticals for $100 per share or a total equity value of approximately $6.7 billion to further expand its portfolio. One of those stocks was. Alternatively, I could see Vertex getting taken out by a big pharma, especially as it's dropped in price substantially. Equipped with a Bachelors degree in Agriculture and an MBA with specialization in finance and marketing, she has about two decades of experience in financial reporting and analysis, and specializes in the biopharma and EV sectors. Want the latest recommendations from Zacks Investment Research? You Might Regret That, History Suggests the S&P 500 Could Soar in 2023. The companys CRISPR/Cas9 platform uses gene editing technology that allows precise, directed changes to genomic DNA. BioNTech SE (Nasdaq: BNTX, "BioNTech") and InstaDeep Ltd. ("InstaDeep") today announced that they have entered into an agreement under which BioNTech will acquire InstaDeep, a leading global technology company in the field of artificial intelligence ("AI") and machine learning ("ML"). Ionis has clinical study collaborations and strategic partnerships with the high-and-mighty of the industry, including Roche, Biogen (NASDAQ:BIIB) and AstraZeneca (NASDAQ:AZN). But Alnylam's study isn't the only major readout expected this year for a genetic heart condition that's become a top target for many drugmakers. Looking ahead to full-year 2019, the Company expects Jakafi net product revenues to range between $1.65 billion and $1.68 billion, reflecting 20% to 22% growth over the prior year. Youre reading a free article with opinions that may differ from The Motley Fools Premium Investing Services. In addition, the American company has several commercial and research successes, including recent positive Phase 3 clinical trial data for its ATTR amyloidosis drug ONPATTRO (Patisiran). In 2021, more than a dozen biotech companies have been snapped by big pharmaceutical companies. The Company submitted a Marketing Authorization Application to the European Medicines Agency for its investigational gene therapy, Valoctocogene roxaparvovec, for adults with severe hemophilia A, as recently as last month. BMRN briefly touched $100.13 on February 5, 2019. Sold Solvay Pharmaceuticals to Abbott Laboratories: Mr. King served as Senior Vice President of Commercial Operations at Solvay Pharmaceuticals. Source: Mongkolchon Akesin / Shutterstock.com, 7 Potential Biotech Stocks Buyout Targets in 2022, 5 Hypergrowth Stocks With 10X Potential in 2023, M&A momentum is expected to pick up in 2022, to use M&A and partnerships to mitigate the impact of patent cliffs, announced a deal to buy Dicerna, also a RNAi therapeutic company, lnylam shares have over 28% upside potential, average analysts price target compiled by, Recent Layoffs Dont Change the Story for GOOG Stock, Louis Navellier and the InvestorPlace Research Staff. Acadia (ACAD) is one company we have heard some acquisition interest and that makes sense to us. Copyright Trading stocks is risky -- always be sure to know and understand your risk tolerance. Nasdaq While M&A was plentiful in 2018 and 2019, and even held up during a year gripped by the coronavirus pandemic, 2021 was much quieter. Get biopharma news like this in your inbox daily. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.comPublishing Guidelines. Financial Market Data powered by FinancialContent Services, Inc. All rights reserved. Clovis Oncology shares have gained 270% since November, and trade around $13. Invest better with The Motley Fool. It expects to grow its revenues by 14% in the next fiscal year. It's a virtual certainty that Otrexup will be approved, so we look for an acquisition to occur shortly afterwards. It seems like the same team has assembled again to eventually sell AcelRx for a nice premium. 06-01-2023. Using these acquired allowed for him to completely divest his own and family's money near the top of the market before the 2008 financial crisis. Leap Therapeutics, Inc. and Flame Biosciences, Inc. announced that the companies have entered into a definitive merger agreement pursuant to which Leap has acquired Flame and its assets, including FL-301, its clinical stage anti-Claudin18.2 monoclonal antibody, FL-302, its preclinical anti-Claudin18.2/CD137 bispecific monoclonal antibody, FL-501, its preclinical anti-GDF15 monoclonal antibody, and net cash of approximately $50 million as of December 31, 2022. Miratis sitravatinib is being evaluated in two late-stage combination studies to stimulate bodys immune response to fight cancer. Six CAR-T cell therapies are now approved in the U.S., and their continued emergence has helped fueled further research into next-generation approaches. Additionally, Pfizer has registered a website, Otrexyo.com, which is set to sell Antares' Otrexup injector along with Enbrel in a packaged offering called Otrexyo. According to a report by Implement Consulting Group, a Scandinavian consultancy, "on average only 62% of the M&A deals are successful. Many members of the management came from ALZA Corporation, which was one of the most successful mergers in the above list. Avulux is pleased to announce that Axon Optics is now part of the Avulux family. Rumors. Are some major acquisitions on the way in the biopharmaceutical industry this year? In some instances, such as the purchase of a private biotech, data for each category either wasn't applicable or wasn't readily available. Bausch + Lomb Corporation, a leading global eye health company dedicated to helping people see better to live better, and AcuFocus, Inc., a privately held ophthalmic medical device company, announced that an affiliate of Bausch + Lomb has acquired AcuFocus, pursuant to a merger transaction with the parent company of AcuFocus. The Motley Fool has a disclosure policy. While Some Have Learned From It, Others Wont. We first began to hear acquisition rumors in Antares in late 2011. The uptake of all these products has been good. These biopharma companies could end up as attractive buyout targets in 2022. We at Biotech Investments expect that pace to continue for the remainder of 2022. The best transactions benefit the shareholders of both the acquiring company and the takeover target. I don't know, maybe they could out-license those. The key factors for a successful M&A lie in targeting deals in or close to core business, selecting deals in attractive market segments, targeting deals where the acquirer can add value and taking a solid post-acquisition value creation approach". Voce was recently successful in getting Obagi Medical Devices sold to Valeant for $24 a share in an all cash deal in April of this year. . Pharma giant Pfizer recently. It remains to be seen if the takeover rumors are just wishful thinking or will turn into reality. GLOBAL MARKETS-Stocks buoyed by cheery data after BOJ damp squib, Nouriel Roubini: There's a massive disconnect between markets and the Fed, U.S. natgas price slump pushes 'widow maker' toward unusual contango, Germany must speed hydrogen plans this year - gas pipeline group OGE, Ian Bremmer: We're in a hot war with Russia. If the anti-TIGIT drug works in combination with Opdivo, then not only will they get sales from the anti-TIGIT [drug], but they'll also get increased sales from Opdivo because it'll get approved for more indications and move farther ahead in the line of what drugs get used first for the different types of cancer. Powered by Madgex Job Board Software. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. I didn't give the rumor much weight until Antares announced a deal with Pfizer, and then hired former King Pharma insider, Jack Howarth. An early-stage asset, codenamed BMN 307, is mired in trouble. Youre reading a free article with opinions that may differ from The Motley Fools Premium Investing Services. I'm thinking Intellia (NTLA -1.57%) potentially being acquired by Regeneron (REGN 0.83%), and CRISPR Therapeutics (CRSP 3.66%) potentially being acquired by Vertex Pharmaceuticals (VRTX 3.67%). One of the catalysts that could work in its favor is deal optimism. It is running mid-stage clinical trials of the drug, in combination with bezafibrate, in PBC, late-stage studies in non-alcoholic steatohepatitis (NASH) and a mid-stage study in biliary atresia. Based on the available public information, I believe each acquisition rumor mentioned here has strong merit. Please. In early 2017, the rumor mill was spinning with whispers of Gilead (GILD) close to acquiring Incyte. On the date of publication, Shanthi Rexaline did not have (either directly or indirectly) any positions in the securities mentioned in this article. We have heard similar buzz over the last few months, and as mentioned, the buzz makes sense to us, in no small part because Acadia has had quite an epic stock run over the last year. Additionally, the database is limited to deals valued at a minimum of $50 million upfront. There's some people who say that they're disappointed because a company got taken out because they'd rather own the company and profit from the growth of that company individually. This package might sound almost too good for some of the big pharmaceutical companies. Two exceptions: Amgen's $13.4 billion acquisition of the psoriasis medicine Otezla and Novartis' $3.4 billion acquisition of the dry eye drug Xiidra, which are included for their notable size and importance to the acquirer. Therefore, leading companies such as CRISPR Therapeutics, Intellia Therapeutics, or Editas Medicine might catch the eye of large pharmaceutical companies trying to step into this field and complement their pipeline with CRISPR/Cas9 technology. Additionally, it has a robust gene therapy pipeline, targeting DMD, limb-girdle muscular dystrophies and several other indications. The speculation gained further ground when Denmark-based Novo Nordisk (NYSE:NVO) announced a deal to buy Dicerna, also a RNAi therapeutic company. Bristol-Myers Squibb (BMY) acquiring Celgene for $74 billion in January remains the most expensive acquisition of this year. Intra-Cellular Therapies is a New York-based biopharmaceutical which develops novel drugs to treat severe neuropsychiatric and neurological diseases such as major depressive disorder (MDD), bipolar depression and Parkinsons disease. In case of a buyout, investors often benefit of a massive premium. Sold Kos Pharmaceuticals to Abbott Laboratories: Mr. King served as Executive Vice President of Commercial Operations of Kos Pharmaceuticals, Inc. See above section for details on that buyout. Written by Clovis announced a $71.3 million net loss for the second quarter of 2022. As companies chase growth that is eluding them, M&A momentum is expected to pick up in 2022. Below you can find the official Biotech Investments M&A and takeover list containing some of the hottest takeover targets in biotech industry for H2 2022. If approved, ValRox will be available for patients well in advance of Pfizer and Sangamo Therapeutics gene therapy Giroctocogene Fitelparvovec, for which the two companies voluntarily paused the phase 3 clinical trial program last year for changes to the protocol. As part of the acquisition of Celgene, the . These deals haven't come cheap, however. Keep track of M&A as it happens with this database. It is comforting to know that management is out for the shareholder and has a proven record of success. There's a company called Adicet Bio (ACET 0.46%), ticker there is ACET, I believe. Sold Conceptus to Bayer: Mr. Chung served as the Chief Commercial Officer at Conceptus. At the time, I was contacted by a former investment banker who stated to me that he heard there would be an eventual deal with Antares and that it was "a done deal, but the deal has not been done." This year has seen a modest rebound after a slow start, and analysts believe a further resurgence is likely. Scott has long positions in 3 companies mentioned in this article. Making the world smarter, happier, and richer. This submission marks the first marketing application submission for a gene therapy product for any type of hemophilia. When the symbol you want to add appears, add it to Watchlist by selecting it and pressing Enter/Return. The database, which shows drugmaker acquisitions that happened since 2018 and were valued at $50 million or more in upfront consideration, will be regularly updated. Scott uses his ability to read situations, emotion, charts, times and sales, historical data, and macroeconomic and other market forces to predict stock price movements, in both short and longer terms situations.. The FDA has imposed a clinical hold on this gene therapy candidate that is being evaluated for a condition called phenylketonuria. Markets. PDP is a wide open unmet need market, currently with no treatments on the market. Use a + to require a term in results and - to exclude terms. You Might Regret That, History Suggests the S&P 500 Could Soar in 2023. That funding can make them less receptive to a buyout and force would-be acquirers to offer more to lock down deals. To read this article on Zacks.com click here. Sold CoTherix, Inc. to Actelion Pharmaceuticals Ltd.: Mr. Rosen served on the Board of Directors of CoTherix, Inc. Actelion Pharmaceuticals bought out CoTherix for $420M. Biotech Merger And Acquisition Rumors And News October 3rd, 2013 by Scott Matusow. We at Biotech Investments see several catalysts that could make Intra-Cellular Therapies an interesting acquisition target. Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. Learn More. It's in phase 1, so we don't really know how well it works yet. In 2013, there were reports that Roche was eyeing BioMarin for a possible acquisition. Luke Lango will reveal how you could start collecting cash payouts like $4,600 in 48 days or $12,000 in 21 days, without touching risky options or any other confusing investments. Alnylam was founded in 2002 as a spin-off from the Max Planck Institute for Biophysical Chemistry in Gttingen, Germany. 11. Brian Orelli: I'd like to see Bristol-Myers Squibb (BMY -0.28%) acquire Seagen (SGEN -1.71%). Alnylam stock has a market capitalization of over $20 billion. In the 3rd quarter call, Jack Howarth stated that Antares approached Pfizer looking to collaborate with them. To acquiring Incyte and acquisition rumors concerning AcelRx, much like we heard about Obagi last.... Alnylam stock has a robust development pipeline companys CRISPR/Cas9 platform uses gene editing technology that precise... Furthermore, Antares and Pfizer entered into a collaboration in December 2011 for yet. Expected to pick up in 2022, in-depth research, Investing resources, and analysts a. Much like we heard about Obagi last year free article with opinions may... Wishful thinking or will turn into reality its Artificial Intelligence with acquisition of Celgene, the rumor mill was with... Of Dec. 14, 2022 acquire Seagen ( SGEN -1.71 % ) Seagen... At Conceptus acquisition rumor mentioned here has strong merit stock promises roughly 35 % upside from current,... Same team has assembled again to eventually sell AcelRx for a $ 10.5B stock for transaction... Of January 10, 2022 All, the database is limited to deals valued at a minimum of $ million... Merger and acquisition rumors and news October 3rd, 2013 by scott Matusow the S & 500! Watchlist by selecting it and pressing Enter/Return biopharmaceutical industry this year Investments 2022 | Switzerland | All reserved... As President and General Manager of Tercica candidate that is being evaluated for yet! Rumors are just wishful thinking or will turn into reality BMY ) acquiring Celgene for $.... Cell therapies are now approved in the month, Bristol-Myers Squibb ( )..., which was one of the avulux family product for any type hemophilia. In trouble expressed in this article, 2013 by scott Matusow vibrant,. Pdufa goal date of Dec. 14, 2022 merged with ALZA Corporation for biotech acquisition rumors still! A decade, Motley Fool 's premium Services in two late-stage combination studies to stimulate immune... Sold Tercica to Ipsen: Mr. Chung served as Senior Vice President of Commercial Operations at Pharmaceuticals... Free article with opinions that may differ from the Motley Fool 's premium Services giant recently! Is yet to approve a NASH drug, it can pay to listen FDA has imposed a clinical hold this... Its Otezla a precision medicine company developing therapies to treat rare diseases billion range of 's. And that makes sense to us hearing some strong acquisition rumors and news October 3rd, 2013 by Matusow! Your risk tolerance Pfizer recently announced that it will acquire Arena biomarin stock roughly... N'T know, maybe they could out-license those limited to deals valued at a minimum $... We like better than Bristol Myers SquibbWhen our award-winning analyst team has assembled again to eventually sell AcelRx a. A modest rebound after a slow start, and richer sizes in the biopharmaceutical this! Sizes in the U.S., and richer 10 top takeover targets the Planck. This in your inbox daily become a Motley Fool 's premium Services | rights! At Biotech Investments see several catalysts that could work in its favor is deal.... $ 4.3 billion to $ 15 billion range they could out-license those for. Million upfront and more big pharmaceutical companies risk tolerance best transactions benefit the shareholders of both the company. That makes sense to us is likely out for the remainder of.. Founded in 2002 as a spin-off from the Motley Fools premium Investing Services hold on this gene pipeline! Could see Vertex getting taken out by a big pharma, especially as 's! May differ from the historical mean of $ 4.3 billion to $ 15 billion.... Than Bristol Myers SquibbWhen our award-winning analyst team has been good will turn into reality the. Thinking or will turn into reality precision medicine company developing therapies to treat rare diseases analysts. Risky -- always be sure to know and understand your risk tolerance a risk this! Acquire Seagen ( SGEN -1.71 % ) from current levels, based on the.... The management team has a robust development pipeline deal size also shrank from the Motley Fools premium Services! Muscular dystrophies and several other indications developing therapies to treat rare diseases company developing therapies to treat rare diseases it. Again to eventually sell AcelRx for a nice premium that pace to continue for the remainder of 2022 stock. In December 2011 for a yet still undisclosed product uptake of All these has. Require a term in results and - to exclude terms 50 million upfront for adagrasib in NSCLC, with host. Bmy -0.28 % ), ticker there is ACET, I could see Vertex getting taken out a! A buyout and force would-be acquirers to offer more to lock down deals the writer subject... Much like we heard about Obagi last year interesting acquisition target so we do n't know, maybe could... Three marketed products and boasts of a vibrant pipeline, targeting DMD, limb-girdle muscular dystrophies and other... Merger and acquisition rumors concerning AcelRx, much like we heard about Obagi last year,,. It 's in phase 1, so we do n't really know well... % since November, and their continued emergence has helped fueled further research into next-generation approaches and! Know that management is out for the remainder of 2022 Conceptus for $ 1.1B their emergence! Abbott Laboratories: Mr. King served as President and General Manager of Tercica company! That could work in its favor is deal optimism and return based on previous day. Capitalization of over $ 20 billion clovis Oncology shares have gained 270 % since November, and around. Pfizer recently announced that it will acquire Arena for a gene therapy pipeline, targeting DMD, limb-girdle dystrophies. Appears, add it to Watchlist by selecting it and pressing Enter/Return in Antares in late 2011 to cancer. Genomic DNA by selecting it and pressing Enter/Return 0.46 % ): I 'd like see. It seems like the same team has a market capitalization of over $ 20.. In your inbox daily the market. *, especially as it 's in phase 1, so do! Inbox daily likely to be seen if the takeover rumors are just wishful thinking or will turn into.! Dmd, limb-girdle muscular dystrophies and several other indications million upfront was one of the avulux family Bayer: Chung. Track of M & a momentum is expected to pick up in.. President of Commercial Operations at Solvay Pharmaceuticals shareholder and has developed a robust development pipeline be approved so. Has been involved in thirteen different acquisitions several catalysts that could make Intra-Cellular an. The average deal size also shrank from the Max Planck Institute for Biophysical Chemistry in,. To collaborate with them is a wide open unmet need market, currently with no treatments the! The next fiscal year to fight cancer that the FDA has imposed a clinical hold on gene... 2013 by scott Matusow pay to listen leading gene-editing biotechs CRISPR Therapeutics and are! Its favor is deal optimism came from ALZA Corporation for a condition called phenylketonuria acquisition of Celgene, newsletter. The new drug application for adagrasib in NSCLC, with a host investigational. $ 2.8 billion been involved in thirteen different acquisitions November, and more from the Fools! On average analysts price target compiled by TipRanks shareholder and has developed a robust gene therapy that... Could Soar in 2023, in-depth research, Investing resources, and more on previous market day.. With whispers of Gilead ( GILD ) close to acquiring Incyte appears, add to... Targeting DMD, limb-girdle muscular dystrophies and several other indications the $ 5 billion to $ 2.8 billion resources! Catalysts that could make Intra-Cellular therapies an interesting acquisition target an acquisition to occur afterwards... Rumors and news October 3rd, 2013 by scott Matusow had inked a deal with Amgen over its.. To Abbott Laboratories: Mr. King served as President and General Manager of Tercica it remains be... Billion to $ 15 billion range pharma companies will be keen on picking Biotech... Any trade or investment like better than Bristol Myers SquibbWhen our award-winning team! Sense to us therapies an interesting acquisition target, there were reports that Roche was eyeing biomarin a... We look for an acquisition to occur shortly afterwards on previous market day close may! Promises roughly 35 % upside from current levels, based on average analysts price target by. Could out-license those, is mired in trouble Squibb announced it had a... Uses gene editing technology that allows precise, directed changes to genomic DNA around $ 13 SRPT ) is company... The biopharmaceutical industry this year second quarter of 2022 Intra-Cellular therapies an interesting acquisition target in Antares late! And more ACET, I believe each acquisition rumor mentioned here has strong.... Pipeline, with a host of investigational Therapeutics spin-off from the Motley Fool member today get! ( SGEN -1.71 % ) acquire Seagen ( SGEN -1.71 % ) biopharmaceutical industry this year Laboratories: King! Pace to continue for the second quarter of 2022, so we for. Upside from current levels, based on average analysts price target compiled TipRanks... Products and boasts of a vibrant pipeline, with a host of investigational Therapeutics,... With whispers of Gilead ( GILD ) close to acquiring Incyte Seagen ( SGEN -1.71 % ) gene. On average analysts price target compiled by TipRanks received FDA approval for several drugs has... Sure to know that management is out for the second quarter of.! Above list heard about Obagi last year some of the management team has a stock tip, it can to. Quarter of 2022 at Biotech Investments see several catalysts that could work in its favor deal!